Bevacizumab BS Nichi-Iko
Bevacizumab biosimilar developed by Nichi-Iko Pharmaceutical. Reference product Avastin.
Brands by market: Bevacizumab BS Nichi-Iko (Japan) · Commercial partner or holder: Nichi-Iko Pharmaceutical
FDAnot listed
EMAnot listed
PMDAJan 2022approved
HCnot listed
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
PMDA
Japan · Bevacizumab BS Nichi-Iko
Pharmaceuticals and Medical Devices Agency and MHLWApprovedBrand
Bevacizumab BS Nichi-Iko
Holder or applicant
Nichi-Iko Pharmaceutical
Pathway
Biosimilar (MHLW approval on PMDA review)
Approved
Jan 2022
Indications as licensed
Colorectal cancer, non-squamous NSCLC
Presentations
100 mg and 400 mg vials
Note
Bevacizumab Biosimilar 3.
Source
S020
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- PMDAJan 2022Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.